Unknown

Dataset Information

0

Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors.


ABSTRACT: Purpose: Insulin-like growth factor 1 (IGF1) signaling regulates breast cancer initiation and progression and associated cancer phenotypes. We previously identified E-cadherin (CDH1) as a repressor of IGF1 signaling and in this study examined how loss of E-cadherin affects IGF1R signaling and response to anti-IGF1R/insulin receptor (InsR) therapies in breast cancer.Experimental Design: Breast cancer cell lines were used to assess how altered E-cadherin levels regulate IGF1R signaling and response to two anti-IGF1R/InsR therapies. In situ proximity ligation assay (PLA) was used to define interaction between IGF1R and E-cadherin. TCGA RNA-seq and RPPA data were used to compare IGF1R/InsR activation in estrogen receptor-positive (ER+) invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) tumors. ER+ ILC cell lines and xenograft tumor explant cultures were used to evaluate efficacy to IGF1R pathway inhibition in combination with endocrine therapy.Results: Diminished functional E-cadherin increased both activation of IGF1R signaling and efficacy to anti-IGF1R/InsR therapies. PLA demonstrated a direct endogenous interaction between IGF1R and E-cadherin at points of cell-cell contact. Increased expression of IGF1 ligand and levels of IGF1R/InsR phosphorylation were observed in E-cadherin-deficient ER+ ILC compared with IDC tumors. IGF1R pathway inhibitors were effective in inhibiting growth in ER+ ILC cell lines and synergized with endocrine therapy and similarly IGF1R/InsR inhibition reduced proliferation in ILC tumor explant culture.Conclusions: We provide evidence that loss of E-cadherin hyperactivates the IGF1R pathway and increases sensitivity to IGF1R/InsR targeted therapy, thus identifying the IGF1R pathway as a potential novel target in E-cadherin-deficient breast cancers. Clin Cancer Res; 24(20); 5165-77. ©2018 AACR.

SUBMITTER: Nagle AM 

PROVIDER: S-EPMC6821389 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors.

Nagle Alison M AM   Levine Kevin M KM   Tasdemir Nilgun N   Scott Julie A JA   Burlbaugh Kara K   Kehm Justin J   Katz Tiffany A TA   Boone David N DN   Jacobsen Britta M BM   Atkinson Jennifer M JM   Oesterreich Steffi S   Lee Adrian V AV  

Clinical cancer research : an official journal of the American Association for Cancer Research 20180625 20


<b>Purpose:</b> Insulin-like growth factor 1 (IGF1) signaling regulates breast cancer initiation and progression and associated cancer phenotypes. We previously identified E-cadherin (<i>CDH1</i>) as a repressor of IGF1 signaling and in this study examined how loss of E-cadherin affects IGF1R signaling and response to anti-IGF1R/insulin receptor (InsR) therapies in breast cancer.<b>Experimental Design:</b> Breast cancer cell lines were used to assess how altered E-cadherin levels regulate IGF1R  ...[more]

Similar Datasets

| S-EPMC4818693 | biostudies-literature
| S-EPMC6497538 | biostudies-literature
| S-EPMC10527942 | biostudies-literature
| S-EPMC7043225 | biostudies-literature
| S-EPMC6638864 | biostudies-literature
| S-EPMC9346469 | biostudies-literature
| S-EPMC6817009 | biostudies-literature
| S-EPMC8169856 | biostudies-literature
| S-EPMC9621571 | biostudies-literature
| S-EPMC4122288 | biostudies-literature